Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system, respiratory, and metabolic diseases. Currently, RVPH is trading at $0.44, with a target price of$0.39, indicating a potential downside of approximately -11.09%. This significant gap between the current and target price suggests a pessimistic outlook from investment analysts, leading to its exclusion from coverage.In comparison, PDS Biotechnology Corpo ...